What sector does Quest Diagnostics belong to?

Quest Diagnostics operates in the Health Care sector, specifically the Health Care Services industry, and is listed on the US markets.

What is the current share price of DGX?

As of the latest available quote, DGX traded at $235.02. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of DGX?

Quest Diagnostics has a price-to-earnings (P/E) ratio of about 24.95. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of DGX?

The market capitalisation of Quest Diagnostics is approximately $26.64B.

Is Quest Diagnostics profitable?

For its latest reported financial year, Quest Diagnostics recorded a net profit margin of about 8.99%.

Does DGX pay a dividend?

Quest Diagnostics currently has a dividend yield of about 1.44%.

What is the return on equity (ROE) of DGX?

Quest Diagnostics has a return on equity (ROE) of about 13.20%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of DGX?

Over the past 52 weeks, DGX has traded between a low of $171.18 and a high of $247.19.

Quest Diagnostics

DGX US Health Care Health Care Services

S&P 500

$235.02

+1.68%

Delayed · cached 15 min

Fair value analysis

DGX

Quest Diagnostics

$235.02

Close used for this calculation

$175.57Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

43/100

Profitability13/25

Returns9/25

Balance Sheet12/25

Efficiency9/25

Growth6/25

Average

Quality radar

Consensus fair value

$175.57

Above FV

▼ -25.3% against the close used

Model range $68.69 – $222.74

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$68.69Fair value$175.57Bull$222.74

FairClose

52-week traded range

52W low $173.4952W high $245.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Quest Diagnostics closed at $235.02, 33.9% above the consensus fair value of $175.57 drawn from 9 valuation models.

Financial DNA score 43/100 — Average. P/E of 26.9x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$222.74

-5.2%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=7.9%, r=10%, tg=3%, n=10yr

Graham Number

$114.98

-51.1%

√(22.5 × EPS × BVPS)

EPS=8.75, BVPS=67.15 · outside Graham range (P/E 26.9, P/B 3.5) — asset-light, treat as a rough floor

P/E Fair Value

$175.00

-25.5%

EPS × 20x (sector P/E)

EPS=8.75, Sector P/E=20x

Peter Lynch (PEG)

$68.69

-70.8%

EPS × Growth% (PEG = 1 is fair)

EPS=8.75, g=7.9%

EV/EBITDA

$214.81

-8.6%

(EBITDA × 13.9x − Net Debt) ÷ Shares

EBITDA=2.13B

Dividend Discount (DDM)

$160.33

-31.8%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=3.2, r=10%, g=7.9%

Book Value (P/B)

$120.87

-48.6%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=67.15, ROE=13.2%, g=6%, r=10%

Reverse DCF

$235.02

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 11.1% | Historical: 7.9%

Margin of Safety

$128.18

-45.5%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=170.91, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer